Pomalidomide plus low-dose Dexamethasone in patients with relapsed and refractory multiple myeloma
The results from the STRATUS trial ( MM-010 ), a single-arm phase IIIb study of Pomalidomide ( Imnovid, Pomalyst ) plus low-dose Dexamethasone in patients with relapsed and refractory multiple myeloma were presented at the 56th American Society of Hematology annual meeting.
In the study, 599 patients with refractory, or relapsed and refractory, disease who had previously failed Lenalidomide and Bortezomib had been enrolled at the time of the data cutoff.
The primary endpoint was safety, and key secondary endpoints included Pomalidomide exposure, overall response rate ( ORR; greater than or equal to partial response ), duration of response ( DOR ), progression-free survival ( PFS ), overall survival ( OS ), and cytogenetic analyses.
Patients had a median five prior therapies. All patients received thromboprophylaxis with low-dose Acetylsalicylic acid ( Aspirin ), low-molecular-weight Heparin ( LMWH ), or equivalent.
The most frequent grade 3-4 adverse events were hematologic, including neutropenia ( 42% ), neutropenic fever ( 5% ), anemia ( 29% ), and thrombocytopenia ( 22% ); grade 3-4 non-hematological toxicities included pneumonia ( 11% ), fatigue ( 5% ), and hypercalcemia ( 4% ).
Grade 3/4 deep vein thrombosis was low ( 1% ) with prophylaxis, and peripheral neuropathy was 1%.
Dose reductions of either Pomalidomide or low dose Dexamethasone due to adverse reactions were required in 18% of patients; 9% of discontinuations were due to adverse reactions 9%.
At a median follow-up of 6.8 months with a median four cycles received, the median progression-free survival and overall survival were 4.2 months and 11.9 months, respectively.
The ORR was 35%, with 8% of patients achieving at least a very good partial response ( VGPR ).
The median DOR was 6.8 months.
In patients refractory to prior Lenalidomide ( n=572 ) or Lenalidomide and Bortezomib ( n=473 ), similar progression-free survival ( 4.2 months and 4.1 months ), overall survival ( 12 months for each ), and ORR ( 34% and 35% ) were achieved.
In addition, a sub-group analysis was conducted to determine the impact of the therapy on patients with moderate renal impairment. Of the 604 patients enrolled in the study, 215 had moderate renal impairment ( creatinine clearance [ CrCl ] greater than 45 mL/min but less than 60 mL/min ).
ORR was generally similar between patient groups receiving Pomalidomide plus low-dose Dexamethasone ( 37% with moderate renal impairment versus 33% without moderate renal impairment ) despite differences in renal function.
The median DOR was 6 months versus 7.9 months, respectively.
Progression-free survival ( was slightly extended in patients without moderate renal impairment, but did not meet statistical significance ( 3.7 versus 4.6 months, p=0.1142 ).
The most common grade 3-4 nonhematologic adverse reactions were infections ( 29% vs. 30% ) and pneumonia ( 12% vs. 11% ).
Twelve percent of patients with moderate renal impairment and 7% of patients without moderate renal impairment discontinued Pomalidomide due to adverse effects.
Pomalidomide starting dose was 4 mg daily for days 1-21 of 28-day cycle. Dexamethasone was given at 40mg/day ( 20 mg for more than 75 years ) on days 1, 8, 15, 22.
Dose intensity was comparable in both groups ( 94% and 93% ). No dose adjustment was required for renal impairment. ( Xagena )
Source: Celgene, 2014
COVID-19 vaccine Janssen - EMA: possible link to very rare cases of unusual blood clots with low blood platelets - Overall benefit-risk remains positive
EMA’s safety committee ( PRAC ) has concluded that a warning about unusual blood clots with low blood platelets should...
The FDA ( Food and Drug Administration ) has approved Fragmin ( Dalteparin sodium ) injection to reduce the recurrence...
Rivaroxaban has demonstrated strong efficacy and safety profile in children with venous thromboembolism
Results from the phase III EINSTEIN-Jr. study has shown a strong efficacy and safety profile of Rivaroxaban ( Xarelto )...
Anthracycline-induced cardiotoxicity was first reported in early 1970s. Since then, there has been increasing recognition of its association with poor...
The FDA ( Food and Drug Administration ) has approved the first pacemaker that does not require the use of...
The European Society of Cardiology ( ESC ) has recommended uninterrupted anticoagulation with vitamin K antagonists during ablation and device...
Patients with atrial fibrillation and venous thromboembolism: non-vitamin K antagonist oral anticoagulants and major bleeding-related fatality
Non-vitamin K antagonist oral anticoagulants ( NOACs ) are efficacious and safe antithrombotic drugs but the non-availability of an antidote...
Patients with cancer and venous thromboembolism: Dabigatran has provided similar clinical benefit as Warfarin
The efficacy and safety of Dabigatran ( Pradaxa ) for treatment of venous thromboembolism ( VTE ) were demonstrated in...
Most ischaemic strokes are caused by a blood clot blocking an artery in the brain. Clot prevention with anticoagulants might...
MATRIX trial: Bivalirudin shows mixed results in patients with acute coronary syndrome. Radial access reduces net adverse events
Two separate clinical trials were presented as a part of ACC.15, and looked at strategies to reduce major bleeding and...